For research use only. Not for therapeutic Use.
PZ-285(CAT: I035293) is a potent anticancer agent with demonstrated efficacy in preclinical models. It exhibits significant potential as a chemotherapeutic agent, showing robust antitumor activity comparable to clinically used doxorubicin (Dox). In vivo, PZ-285 enhances survival, inhibits primary tumor regrowth, and effectively suppresses lung tumor metastasis. Its multifaceted activity highlights its potential for treating various cancers. PZ-285 is a valuable compound for oncology research, offering insights into novel chemotherapeutic mechanisms and therapeutic strategies to improve cancer treatment outcomes, particularly in addressing metastasis and tumor recurrence.
| Synonyms | PZ-285; PZ 285; PZ285; Pz-285; Pz 285; Pz285; Porphyrazine Diol; H2Pz(A3B) |
| Molecular Formula | C42H50N8O14 |
| Purity | 98% |
| Solubility | Soluble in DMSO |
| Appearance | Solid powder |
| Storage | Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years). |
| IUPAC Name | 2-[(6R,7R,15R,16R,24R,25R)-35-(2-hydroxyethyl)-6,7,15,16,24,25-hexamethoxy-6,7,15,16,24,25-hexamethyl-5,8,14,17,23,26-hexaoxa-2,11,20,29,37,38,39,40-octazanonacyclo[28.6.1.13,10.112,19.121,28.04,9.013,18.022,27.031,36]tetraconta-1,3(40),4(9),10,12,18,20,22(27),28,30(37),31,33,35-tridecaen-32-yl]ethanol |
| InChI | InChI=1S/C42H50N8O14/c1-37(53-7)39(3,55-9)61-25-23(59-37)31-44-29-21-19(15-17-51)13-14-20(16-18-52)22(21)30(43-29)45-32-24-26(62-40(4,56-10)38(2,54-8)60-24)34(47-32)49-36-28-27(35(50-36)48-33(25)46-31)63-41(5,57-11)42(6,58-12)64-28/h13-14,51-52H,15-18H2,1-12H3,(H2,43,44,45,46,47,48,49,50)/t37-,38-,39-,40-,41-,42-/m1/s1 |
| InChIKey | PURPDMVLMICIQP-GIEDQAFWSA-N |
| SMILES | C[C@@]([C@](C)(OC)O1)(OC)OC(/C2=N/C3=N/C(C4=C3O[C@@](C)(OC)[C@](C)(OC)O4)=N5)=C1/C(N2)=N/C(C6=C/7C(CCO)=CC=C6CCO)=NC7=N/C8=C(O[C@@](C)(OC)[C@](C)(OC)O9)C9=C5N8 |
